The impact of the duration of the integrated disease management program on COPD-related outcomes

被引:0
|
作者
Lin, Ching-Hsiung [1 ,2 ,3 ,4 ]
Li, Yi-Rong [5 ]
Wang, Bing-Yen [6 ]
Lin, Sheng-Hao [1 ,4 ]
Huang, Kuo-Yang [1 ,4 ]
Chen, Cheng-Hsiung [1 ]
Kor, Chew-Teng [7 ,8 ]
机构
[1] Changhua Christian Hosp, Dept Internal Med, Div Chest Med, 135 Nanhsiao St, Changhua 50006, Taiwan
[2] Natl Chung Hsing Univ, Inst Genom & Bioinformat, Taichung, Taiwan
[3] Natl Chung Hsing Univ, Taichung, Taiwan
[4] MingDao Univ, Dept Recreat & Holist Wellness, Changhua, Taiwan
[5] Changhua Christian Hosp, Thorac Med Res Ctr, Changhua 500, Taiwan
[6] Changhua Christian Hosp, Dept Surg, Div Thorac Surg, Changhua 500, Taiwan
[7] Changhua Christian Hosp, Big Data Ctr, Changhua 500, Taiwan
[8] Natl Changhua Univ Educ, Grad Inst Stat & Informat Sci, Changhua 500, Taiwan
关键词
COPD; Integrated care model; Intervention duration; MCID improvement for CAT; Exacerbation; EXACERBATIONS;
D O I
10.1186/s40001-023-01136-0
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundThe aim of this study is to assess the impact of the duration of the integrated disease management (IDM) program on COPD-related outcomes in real-world setting.MethodsA retrospective cohort study among 3771 patients with COPD who had regularly completed 4 visits of IDM program within 1 year between April 1, 2017 and December 31, 2018. CAT score as the primary outcome used to investigate the association between IDM intervention duration and improvement in CAT score. Change in CAT score from baseline to each follow-up visit determined by using least-squares means (LSMeans) approach. The cut-off value of IDM duration for improving the CAT score was determined by the Youden index. Logistic regression was used to analyze the relationship between IDM intervention duration and MCID (the minimal clinically important difference) improvement in CAT score and the factor associated CAT improvement. Risks of COPD exacerbation events (COPD-related ED visit and COPD-related hospitalization) were estimated by using the cumulative incidence curve and Cox proportional hazards models.ResultAmong 3771 enrolled COPD patients, the majority of the study cohort were males (91.51%) and 42.7% of patients had CAT score of >= 10 at baseline. The mean of age was 71.47 years and the mean CAT at baseline were 10.49. The mean change from baseline in CAT score was - 0.87, - 1.19, - 1.23 and - 1.40 at 3-, 6-, 9- and 12 month follow-up (p < 0.0001 for all visits), respectively. Statistically significantly lower likelihood of achieving MCID improvement in CAT were observed at 3- and 6 month compared to 9 month (at 3 month: OR: 0.720, 95% CI 0.655-0.791; at 6 month: OR: 0.905, 95% CI 0.825-0.922). And only a modest increase likelihood of achieving MCID improvement in CAT at 12 month (OR: 1.097, 95% CI 1.001-1.201) compared with 9-month follow-up. In logistic regression on the entire cohort, CAT MCID improvement was most associated with baseline CAT scores >= 10, followed by frequent exacerbation in previous year (> 2 episodes/year), wheezing, and GOLD B or D at baseline. In baseline CAT >= 10 group, patients were more likely to achieve CAT MCID improvement and had greater decreases from baseline in CAT score observed at 3-, 6-, 9-, and 12 month compared with baseline CAT score < 10 group (all p < 0.0001). Moreover, in CAT >= 10 groups, patients who achieved CAT MCID improvement had lower risk of subsequent COPD exacerbation events (COPD-related ED visit: aHR: 1.196, 95% CI 0.985-1.453, p = 0.0713; COPD-related hospitalization: aHR: 1.529, 95% CI 1.215-1.924, p = 0.0003) when compared to those without.ConclusionThis is the first real-world study indicating the association between COPD IDM intervention duration and COPD-related outcomes. From 3 to 12 month follow-up results showed that continued improvement over time in COPD-specific health status, particularly in patients with baseline CAT score of >= 10. Furthermore, a reduction of the risk of subsequent COPD exacerbations were observed in patients with CAT MCID improvement.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] An integrated disease management (IDM) programme of 12 months duration was effective for patients with COPD
    Porcu, Anna
    Conti, Barbara
    Vignale, Luigi
    Rocchi, Alberto
    Polselli, Mariella
    Marsiglia, Biagio
    Casani, Aldo
    Moretti, Maurizio
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [22] Impact of an Integrated Care Program (AIREPOC) on COPD Outcomes According to Wood or Tobacco Exposure
    Torres-Duque, C. A.
    Pachon, A.
    Rodriguez, C.
    Aguirre, C.
    Huertas, S.
    Mejia, A.
    Quintero, E. Tuta
    Gonzalez-Garcia, M.
    Casas, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [23] Lower Health Literacy Among COPD Patients Is Associated With Poorer COPD Functional Outcomes And Greater Risk Of COPD-Related Emergency Utilization
    Omachi, T. A.
    Sarkar, U.
    Yelin, E. H.
    Blanc, P. D.
    Katz, P. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [24] Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA
    Stanford, Richard H.
    Parker, Emily D.
    Reinsch, Tyler K.
    Buikema, Ami R.
    Blauer-Peterson, Cori
    RESPIRATORY MEDICINE, 2019, 150 : 1 - 7
  • [25] Diabetes Associated With Higher Health Care Utilization and Poor Outcomes After COPD-Related Hospitalizations
    Belligund, Pooja
    Attaway, Amy
    Lopez, Rocio
    Damania, Dushyant
    Hatipoglu, Umur
    Zein, Joe G.
    AMERICAN JOURNAL OF MANAGED CARE, 2022, 28 (09): : E325 - +
  • [26] Impact of leuprolide acetate disease management program on patient outcomes
    Nolbert, M
    Wells, P
    Hussein, G
    CLINICAL RESEARCH AND REGULATORY AFFAIRS, 2002, 19 (01) : 33 - 42
  • [27] COPD-related fatigue: Impact on daily life and treatment opportunities from the patient's perspective
    Kouijzer, Marileen
    Brusse-Keizer, Marjolein
    Bode, Christina
    RESPIRATORY MEDICINE, 2018, 141 : 47 - 51
  • [28] One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program
    Groeneweg, Marti
    Forrester, Sara H.
    Arnold, Beth
    Palazzo, Lorella
    Zhu, Weiwei
    Yoon, Paul
    Scearce, Tim
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (05): : 458 - 463
  • [29] Pharmacist impact on clinical outcomes in a diabetes disease management program.
    Kiel, P
    McCord, AD
    PHARMACOTHERAPY, 2004, 24 (10): : 1474 - 1475
  • [30] The impact of integrated disease management in high-risk COPD patients in primary care
    Ferrone, Madonna
    Masciantonio, Marcello G.
    Malus, Natalie
    Stitt, Larry
    O'Callahan, Tim
    Roberts, Zofe
    Johnson, Laura
    Samson, Jim
    Durocher, Lisa
    Ferrari, Mark
    Reilly, Margo
    Griffiths, Kelly
    Licskai, Christopher J.
    Atkins, Andrew
    Baker, Bill
    Dalo, Sara
    Piccinato, Jean
    Waddick, Denise
    Wong, Brice
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2019, 29 (1)